Stabilized alpha helical peptides and uses thereof
Novel polypeptides and methods of making and using the same are described herein. The polypeptides include cross-linking (“hydrocarbon stapling”) moieties to provide a tether between two amino acid moieties, which constrains the secondary structure of the polypeptide. The polypeptides described herein can be used to treat diseases characterized by excessive or inadequate cellular death.
1. A method of treating leukemia in a subject comprising administering to a subject in need thereof a therapeutically effective amount of a cross-linked polypeptide, wherein the cross-linked polypeptide has increased cell permeability compared to a corresponding uncrosslinked polypeptide and wherein the cross-linked polypeptide has the formula:
wherein;
each R 1 and R 2 are independently H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroarylalkyl, or heterocyclylalkyl;
R 3 is alkyl, alkenyl, alkynyl; [R 4 —K—R 4 ] or a naturally occurring amino acid side chain;
each of which is substituted with 0-6 R 5 ;
R 4 is alkyl, alkenyl, or alkynyl;
R 5 is halo, alkyl, OR 6 , N(R 6 ) 2 , SR 6 , SOR 6 , SO 2 R 6 , CO 2 R 6 , R 6 , a fluorescent moiety, or a radioisotope;
K is O, S, SO, SO 2 , CO, CO 2 , CONR 6 , or
R 6 is H, alkyl, or a therapeutic agent;
R 7 is alkyl, alkenyl, alkynyl; [R 4 —K—R 4 ] or a naturally occurring amino acid side chain;
each of which is substituted with 0-6 R 5 ;
n is an integer from 1-4;
x is an integer from 2-10;
each y is independently an integer from 0-100;
z is an integer from 1-10; and
each Xaa is independently an amino acid;
wherein the polypeptide has a substantially alpha helical secondary structure in aqueous solution.